SCHEMBL6311310

SCHEMBL6311310

COc1ccc(C(O)c2ccc3cc(OC)ccc3c2)c(F)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB11 O95342 1/20 0.50
AKR1C3 P42330 7/20 0.49
AKR1C2 P52895 7/20 0.49
PTGS2 P35354 3/20 0.49
PTGS1 P23219 3/20 0.49
TSHR P16473 2/20 0.49
CYP1A2 P05177 2/20 0.49
CDC42 P60953 1/20 0.49
RAC1 P63000 1/20 0.49
SLC22A6 Q4U2R8 1/20 0.49
LMNA P02545 1/20 0.47
MAPT P10636 1/20 0.47
CYP2C9 P11712 1/20 0.47
AKR1C1 Q04828 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
ALOX5 P09917 2/20 0.43
CYP2A6 P11509 1/20 0.42
MTNR1A P48039 2/20 0.41
MTNR1B P49286 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8072598 0.81 MTNR1B (0.42) AKR1C3AKR1C2PTGS1LMNAAKR1C1
SCHEMBL28512510 0.81 ABCB11 (0.53) ABCB11AKR1C3AKR1C2PTGS2PTGS1
SCHEMBL3949900 0.78 ABCB11 (0.42) ABCB11AKR1C3AKR1C2PTGS2PTGS1
SCHEMBL6376525 0.78 MTNR1A (0.42) CYP1A2MAPTMTNR1AMTNR1B
SCHEMBL29859207 0.76 ADRA2A (0.45) PTGS2PTGS1CYP1A2MTNR1AMTNR1B
SCHEMBL28745848 0.76 CPS1 (0.42) CYP1A2MTNR1AMTNR1B
SCHEMBL2292153 0.76 ADRA2A (0.45) PTGS2PTGS1CYP1A2MTNR1AMTNR1B
SCHEMBL5359575 0.76 NPC1 (0.45) L3MBTL1
SCHEMBL3284398 0.76 AKR1C3 (0.57) ABCB11AKR1C3AKR1C2PTGS2PTGS1
SCHEMBL23255697 0.74 ABCB11 (0.66) ABCB11AKR1C3AKR1C2PTGS2PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050272786-A1 Naphthyl benzoxazoles and benzisoxazoles as estrogenic agents WYETH (US) 2005-12-08 US disclosed
US-6960607-B2 Naphthyl benzoxazoles and benzisoxazoles as estrogenic agents WYETH (US) 2005-11-01 US disclosed
US-20030171412-A1 Naphthyl benzoxazoles and benzisoxazoles as estrogenic agents WYETH 2003-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171412-A1 Naphthyl benzoxazoles and benzisoxazoles as estrogenic agents ESR1, ESR2, ESRRA ABCB11 300/4885AKR1C3 1063/4885AKR1C2 1240/4885
US-20050272786-A1 Naphthyl benzoxazoles and benzisoxazoles as estrogenic agents ESR1, ESRRA, ESR2 ABCB11 236/4885AKR1C3 534/4885AKR1C2 784/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.